𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of bone metastases in carcinoma of breast

✍ Scribed by I. J. Diel; E.-F. Solomayer; C. Gollan

Publisher
Springer
Year
1999
Tongue
German
Weight
119 KB
Volume
32
Category
Article
ISSN
0017-5994

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who

Mechanisms of osteolytic bone metastases
Mechanisms of osteolytic bone metastases in breast carcinoma
✍ Sanna-Maria KΓ€kΓΆnen; Gregory R. Mundy πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 102 KB

Osteolytic and osteoblastic metastases are often the cause of considerable morbidity in patients with advanced prostate and breast carcinoma. Breast carcinoma metastasis to bone occurs because bone provides a favorable site for aggressive behavior of metastatic cancer cells. A vicious cycle arises b